Q-omics provides the consensus-scored SPRR2F profile across patient tissues and cancer cell-line models. SPRR2F expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SPRR2F is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, SPRR2F RNA expression shows 8,965 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, LUSC, and ESCA as cancer lineages where SPRR2F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRR2F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRR2F survival associations across molecular data types. SPRR2F RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRR2F RNA expression–survival associations across cancer types. High SPRR2F expression shows unfavorable associations in KIRP, KIRC, SKCM, KICH and PAAD, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for SPRR2F RNA expression.
This table summarizes SPRR2F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRR2F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRR2F shows lower tumor expression in BRCA, STAD and KIRC and higher tumor expression in LUSC, BLCA and LUAD. The LUSC box plot shows higher SPRR2F RNA expression in tumor versus normal tissue (log2 FC = +3.119, t-test p < 0.001).
This table shows molecular features associated with SPRR2F in patient tissues and cancer cell lines. In patient samples, SPRR2F shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRR2F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
